Increased c-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML

被引：29

作者：

Advani, Anjali S. ^{[1
]}

Rodriguez, Cristina ^{[1
]}

Jin, Tao ^{[1
]}

Abou Jawde, Rony ^{[1
]}

Saber, Wael ^{[1
]}

Baz, Rachid ^{[1
]}

Kalaycio, Matt ^{[1
]}

Sobecks, Ronald ^{[1
]}

Sekeres, Mikkael ^{[1
]}

Tripp, Barbara ^{[1
]}

Hsi, Eric ^{[1
]}

机构：

[1] Cleveland Clin CCF, Leukemia Program, Taussig Canc Ctr, Cleveland, OH 44195 USA

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 06期

关键词：

c-kit; acute myelogenous leukemia; prognosis; MFI; tyrosine kinase;

D O I：

10.1016/j.leukres.2007.08.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

C-kit, a tyrosine kinase receptor, is expressed on most myeloid blasts and is thought to be important in the pathogenesis of AML. Activation of the c-kit receptor leads to phosphorylation and activation of downstream signaling proteins, which are important for cell survival and proliferation. Here, we discuss the prognostic impact of c-kit intensity, measured using the mean fluorescent index (MFI) in patients with newly diagnosed AML. On multivariate analysis, c-kit MFI > 20.3 correlated with a decreased progression-free survival and overall survival, independent of known prognostic factors (age, white blood count at diagnosis and cytogenetics). Whether inhibiting c-kit in patients with AML will after prognosis is the basis of ongoing clinical trials. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：913 / 918

页数：6

共 30 条

[1]

FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications [J].

Advani, AS .

CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) :3449-3457

[2]

EXPRESSION OF A 150-KD CELL-SURFACE ANTIGEN IDENTIFIED BY MONOCLONAL-ANTIBODY YB5.B8 IS ASSOCIATED WITH POOR PROGNOSIS IN ACUTE NON-LYMPHOBLASTIC LEUKEMIA [J].

ASHMAN, LK ;

ROBERTS, MM ;

GADD, SJ ;

COOPER, SJ ;

JUTTNER, CA .

LEUKEMIA RESEARCH, 1988, 12 (11-12) :923-928

[3]

BUHRING HJ, 1993, CANCER RES, V53, P4424

[4]

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[5]

THE C-KIT LIGAND SUPPRESSES APOPTOSIS OF HUMAN NATURAL-KILLER-CELLS THROUGH THE UP-REGULATION OF BCL-2 [J].

CARSON, WE ;

HALDAR, S ;

BAIOCCHI, RA ;

CROCE, CM ;

CALIGIURI, MA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) :7553-7557

[6]

HLA-DR ANTIGEN EXPRESSION ON PERIPHERAL-BLOOD MONOCYTES CORRELATES WITH SURGICAL INFECTION [J].

CHEADLE, WG ;

HERSHMAN, MJ ;

WELLHAUSEN, SR ;

POLK, HC .

AMERICAN JOURNAL OF SURGERY, 1991, 161 (06) :639-645

[7]

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) [J].

Del Poeta, G ;

Venditti, A ;

Del Principe, MI ;

Maurillo, L ;

Buccisano, F ;

Tamburini, A ;

Cox, MC ;

Franchi, A ;

Bruno, A ;

Mazzone, C ;

Panetta, P ;

Suppo, G ;

Masi, M ;

Amadori, S .

BLOOD, 2003, 101 (06) :2125-2131

[8]

Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other [J].

Domen, J ;

Weissman, IL .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (12) :1707-1718

[9]

High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis [J].

Graf, M ;

Reif, S ;

Hecht, K ;

Pelka-Fleischer, R ;

Pfister, K ;

Schmetzer, H .

AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (01) :26-35

[10]

Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia [J].

He, XY ;

Pohlman, B ;

Lichtin, A ;

Rybicki, L ;

Kalaycio, M .

LEUKEMIA, 2003, 17 (06) :1078-1084

← 1 2 3 →